SeraNovo And AstraZeneca To Collaborate On Research Projects

SeraNovo is pleased to announce the closing of a multicompound deal with AstraZeneca (Cambridge, United Kingdom).

Leiden, May 15th , 2023:


SeraNovo and AstraZeneca to collaborate on research projects


SeraNovo (Leiden, The Netherlands) is pleased to announce the closing of a multicompound deal with AstraZeneca (Cambridge, United Kingdom).

Niall Hodgins, Chief Executive Officer of SeraNovo commented: “SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous relationship with AstraZeneca.”

About SeraNovo: SeraNovo is a formulation technology provider that enhances the bioavailability of poorly soluble Active Pharmaceutical Ingredients (APIs). Our team specializes in addressing two core issues with our proprietary technology: enhancing bioavailability and reducing development time to the clinic. As the inventor of this technology, SeraNovo owns the associated know-how and intellectual property. For more information, please visit About AstraZeneca: AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. For more information, please visit


Forward-Looking Statements: This press release contains forward-looking statements, including but not limited to statements regarding development plans, formulation platforms, and product candidates and related capabilities. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from current expectations and projections. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required by law

For further information, please contact Niall Hodgins – CEO
E-mail -